1. Introduction {#sec1-ijerph-12-15048}
===============

E-cigarettes usually provide nicotine and potentially act as a replacement for smoking. They are battery powered devices that aim to simulate tobacco cigarettes, essentially by heating a solution containing nicotine into an inhalable aerosol \[[@B1-ijerph-12-15048],[@B2-ijerph-12-15048]\]. Available evidence, so far, suggests that e-cigarettes are much safer than tobacco because the constituents of cigarette smoke that are harmful are either absent or present at much lower levels in e-cigarettes and the chemicals present in e-cigarettes have not, at least as yet, been shown to be harmful \[[@B3-ijerph-12-15048],[@B4-ijerph-12-15048],[@B5-ijerph-12-15048]\]. They have also not become a significant gateway to smoking cigarettes for non-smokers \[[@B4-ijerph-12-15048]\]. Furthermore at least some types of e-cigarettes might help smokers to quit or at least reduce their cigarette use \[[@B3-ijerph-12-15048],[@B5-ijerph-12-15048],[@B6-ijerph-12-15048]\]. Meta-analysis of randomised control trials \[[@B7-ijerph-12-15048]\] has shown that e-cigarettes are similar in efficacy to patches for quitting and are better than patches for reducing the number of cigarettes smoked and quitting and harm reduction are more likely when e-cigarettes contain nicotine; however the small number of trials means that more trials are required. In 2015 there were about 2.6 million e-cigarette users in Great Britain \[[@B8-ijerph-12-15048]\]. Among a survey sample of smokers and ex-smokers in England a fifth were current users and a third had tried them \[[@B9-ijerph-12-15048]\]. E-cigarettes are now, by a considerable margin, the approach to quitting most favoured by smokers in England \[[@B10-ijerph-12-15048]\].

A small proportion of smokers (about 5% of those making a quit attempt \[[@B10-ijerph-12-15048]\]) are willing to access local stop smoking services (SSS) for help with their quit attempt, but this still amounted to 450,582 clients in 2014/2015 \[[@B11-ijerph-12-15048]\]. SSS treated 816,444 smokers in 2011/12 \[[@B11-ijerph-12-15048]\] and thus use has almost halved between 2011/12 and 2014/15. At the same time e-cigarette use has grown, however, during this period the SSS have also undergone other changes such as being transferred from the NHS to Local Authorities. Nevertheless, smokers attending SSS have a greater chance of quitting than smokers attempting to stop by using medication or willpower alone \[[@B12-ijerph-12-15048],[@B13-ijerph-12-15048],[@B14-ijerph-12-15048]\] and a growing number of countries are offering cessation support \[[@B15-ijerph-12-15048]\]. Thus the reported experience of smokers already willing to use SSS, a cessation aid which has empirical support \[[@B16-ijerph-12-15048]\], regarding e-cigarettes may be particularly valuable.

The National Centre for Smoking Cessation Training (NCSCT) recommends that SSS "be open to electronic cigarette use in people keen to try them; especially in those that have tried, but not succeeded, in stopping smoking with the use of licensed stop smoking medicines" \[[@B17-ijerph-12-15048]\]. However the safety of e-cigarettes is still debated \[[@B18-ijerph-12-15048]\] and the ensuing confusion among potential consumers may be the reason for the current plateauing of growth \[[@B19-ijerph-12-15048],[@B20-ijerph-12-15048]\]. Previous research suggests that SSS are a source of information and advice on e-cigarettes for smokers \[[@B21-ijerph-12-15048]\] and as such it is important to understand the knowledge of, and attitudes towards, e-cigarettes held by stop smoking practitioners.

The aims of this paper are to explore: Reported extent and efficacy of e-cigarette use among Stop Smoking Service clientsSSS personnel's knowledge and attitudes towards e-cigarettes and which groups are more likely to be positive about e-cigarettesWhether SSS personnel view e-cigarettes as having an impact on the recent reduction in SSS use by smokers wishing to quit

2. Experimental Section {#sec2-ijerph-12-15048}
=======================

2.1. Data {#sec2dot1-ijerph-12-15048}
---------

### 2.1.1. Local Stop Smoking Services Quarterly Returns {#sec2dot1dot1-ijerph-12-15048}

Quarterly monitoring returns of the local stop smoking services data (April to June and July to September 2014) were analysed. Four times a year, SSS send data on the number of clients who have set a quit date (named a day when they will attempt to quit smoking) and how many of these had quit smoking four weeks later to the NHS Health and Social Care Information Centre. Clients can be counted in national monitoring data if they are an adult who has been smoking a tobacco product daily or an adolescent who has been smoking a tobacco product weekly and they have not quit smoking more than 48 hours prior to attending their first session \[[@B12-ijerph-12-15048]\]. A client is regarded as a four week quitter if they self-report that they have not smoked within the previous two weeks and an expired air carbon monoxide test reading is 10ppm or below \[[@B12-ijerph-12-15048]\]. The information is originally collected by each SSS client's practitioner either electronically using data monitoring software or via paper forms. Since 1st April 2013, this data collation has not been mandatory but the majority of services continue to send information \[[@B12-ijerph-12-15048]\].

From 1st April 2014, services were asked to include whether SSS clients were using e-cigarettes and similar products, such as nicotine strips for oral use, which together were called "unlicensed nicotine containing products" in addition to continuing to record if they were using licensed medications (nicotine replacement therapy (NRT), Bupropion or Varenicline) \[[@B12-ijerph-12-15048]\]. Note that, currently, e-cigarettes account for virtually all unlicensed nicotine containing products. Clients could also use different combinations of licenced and unlicensed products and these are also recorded.

### 2.1.2. Online Survey {#sec2dot1dot2-ijerph-12-15048}

An e-bulletin was sent to 24,000 SSS practitioners, managers, and commissioners registered with the NCSCT containing an invitation to participate and a link to an online survey. Practitioners directly provide behavioural support for smokers wanting to quit. Managers may have direct contact with smokers through supervising practitioners. Commissioners work for the local authority and make decisions about who will run the service and are less likely to have direct contact with clients. The survey was completed 1801 times between 26 November and 15 December 2014. After exclusions for missing data and locations outside England there were 1761 cases available for analysis. This represents a 7% response rate or one in every 14 of those invited.

2.2. Analysis {#sec2dot2-ijerph-12-15048}
-------------

The software used for analysis was SPSS version 22. The data collected in the online survey will be deposited with the University of Bath Research Archive.

### 2.2.1. Local Stop Smoking Services Quarterly Returns {#sec2dot2dot1-ijerph-12-15048}

Frequencies and four-week quit rates were calculated by the nicotine containing product (NCP) used. The categories available were single licensed NCP only, combination of licensed NCPs concurrently, Bupropion (Zyban) only, Varenicline (Champix) only, licensed NCP and/ or Bupropion (Zyban) and/or Varenicline (Champix) consecutively, combination of a licensed medication and an unlicensed NCP concurrently, licensed medication and an unlicensed NCP consecutively, unlicensed NCP only, did not use any licensed medication, or unlicensed NCP, not known. Additionally, the total setting quit dates and quitting for clients using an unlicensed NCP alone or in combination with other medications was calculated. Clients who are lost to follow up are included in the denominator in an "intention to treat" approach \[[@B22-ijerph-12-15048]\].

### 2.2.2. Online Survey {#sec2dot2dot2-ijerph-12-15048}

Univariate results and column percentages were tabulated. For most questions, respondents were asked to tick as many as applied and for these the number and proportion that ticked each box are tabulated. For some questions, clients were asked whether they agreed with a list of statements and answered on a five point Likert scale. For analysis, these were dichotomised into strongly agree and agree and compared with neither agree nor disagree, disagree, and strongly disagree.

Opinion of e-cigarettes was the dependent variable for most of the analysis. Opinion of e-cigarettes was derived from responses to how much respondents agreed with the statement that e-cigarettes are a good thing. Respondents who held a positive opinion of e-cigarettes if they said they strongly agreed or agreed were compared with respondents who said they neither agreed nor disagreed, disagreed, or strongly disagreed. Chi-square tests, with the continuity correction applied for two by two tables, were conducted between opinion of e-cigarettes and sources of information on e-cigarettes, (possible sources were NCSCT briefing and website, the news and media, training courses, ASH briefing and website, WHO report on electronic cigarettes, experienced electronic cigarette users, the websites of electronic cigarette companies, the websites of vaping organisations); whether respondents agreed or strongly agreed (compared with neither agreed or disagreed, disagreed or strongly disagreed) that: "e-cigarettes should not be recommended by SSS until there is good evidence on safety and effectiveness", "if an e-cig was a licensed medication, I would definitely recommend them to clients", "e-cigarettes should only be available as a licensed medication", "e-cigarettes normalise cigarette smoking", "over the past twelve months, I've become less positive about e-cigarettes", "e-cigarettes are a good thing", "e-cigarettes should be able to be bought anywhere by smokers as a consumer product" and "e-cigarettes denormalise cigarette smoking"; client groups to which respondents would recommend e-cigarettes (possible groups were all my clients, clients who are already using e-cigarettes, clients wishing to cut down but not stop, clients wanting to use electronic cigarettes at times when they cannot smoke (temporary abstinence), clients who wish to cut down before they stop, clients who have tried and failed to quit many times, more dependent smokers, none of my clients); region of England (North East, North West, Yorkshire & Humberside, East Midlands, West Midlands, East of England, London, South East, South West), employer organization (General Practice, Pharmacy, Acute/Foundation Hospital Trust, Employed directly by the Local Authority, Mental Health Trust, Private company, Social enterprise, Other) and professional role (Commissioner, Manager, Stop Smoking Practitioner, Other). Regional differences have been found for preferred tobacco product \[[@B23-ijerph-12-15048]\] and smoking prevalence \[[@B24-ijerph-12-15048]\] and area differences have been found for smoking cessation \[[@B13-ijerph-12-15048]\]. Thus regional differences for e-cigarettes were plausible and included in the analysis. Differences have also been found for cessation according to stop smoking service provider \[[@B13-ijerph-12-15048],[@B25-ijerph-12-15048]\] so employer organisation was included and analysed. In preparation for multivariate analyses chi-square tests were also conducted between each of the variables and professional role in the services.

There was also univariate analyses of reasons for the decline in e-cigarette use (reasons were smokers choosing to use e-cigarettes, remaining smokers in the population are harder to reach, reduced mass media health campaigns, reduced funding of services, SSS moved from NHS to LA, SSS put out to tender and few specialist practitioners available).

### 2.2.3. Multivariate Analysis---Which Variables Affect the Association between Role in the Service and Opinion of E-Cigarettes {#sec2dot2dot3-ijerph-12-15048}

Logistic regression analysis, with opinion on e-cigarettes as the outcome, was carried out. Variables were candidates to be included in the model where they were significantly associated with opinion on e-cigarettes and role in the services in bivariate analysis. The following stages took place: Firstly, cases which were missing on any variable, or whose role in the service was "other" were excluded leaving 1278 cases. Secondly, each variable was placed alone in the model. Thirdly, each variable was placed in the model with role in the service and the change in the odds ratio of role in the service was noted. Fourthly, the variables were added in a stepwise fashion; variables were entered in the order of the size of the difference made to the odds ratio of role in the service in the second stage. When the odds ratio of role in the service was non-significant (*p* \< 10) no more independent variables were entered into the model. The relative importance of the variables was checked using backwards stepwise entry.

3. Results and Discussion {#sec3-ijerph-12-15048}
=========================

3.1. Local Stop Smoking Services Quarterly Returns {#sec3dot1-ijerph-12-15048}
--------------------------------------------------

Of the 207,883 clients who set quit dates between April and September 2014, 4750 reported using electronic cigarettes ([Table 1](#ijerph-12-15048-t001){ref-type="table"}). There were 874 clients who reported using electronic cigarettes only, 3122 who used them concurrently with a licenced medication and 874 who reported used them consecutively with a licenced medication (the data does not allow us to determine whether e-cigarettes were used first or second). Self report quit rates for those using electronic cigarettes (59%) were higher than general (50%) and similar to those using Varenicline alone (60%).

ijerph-12-15048-t001_Table 1

###### 

English local Stop Smoking Services monitoring data April to September 2014.

  Type of Pharmacotherapy                                                            Set Quit Date   Quit at 4 Weeks   \% Quit
  ---------------------------------------------------------------------------------- --------------- ----------------- ---------
  Total                                                                              207,883         103,899           50%
  Single NCP only                                                                    60,513          28,954            48%
  Combination of licensed NCPs concurrently                                          62,771          28,728            46%
  Bupropion (Zyban) only                                                             1047            582               56%
  Varenicline (Champix) only                                                         53,215          32,002            60%
  Licensed NCP and/or Bupropion (Zyban) and/or Varenicline (Champix) consecutively   3542            1674              47%
  Combination of a licensed medication and an unlicensed NCP concurrently            3122            1756              56%
  Licensed medication and an unlicensed NCP consecutively                            754             464               62%
  Unlicensed NCP only                                                                874             570               65%
  Did not use any licensed medication or unlicensed NCP                              11,716          6314              54%
  Not known                                                                          10,329          2855              28%
  Unlicensed NCP with and without other medication                                   4750            2790              59%
  \% Total clients using NCP                                                         2%              3%                

3.2. Online Survey {#sec3dot2-ijerph-12-15048}
------------------

### 3.2.1. Respondent Knowledge and Attitudes {#sec3dot2dot1-ijerph-12-15048}

The most frequently mentioned source of information on e-cigarettes, mentioned by about two-thirds of respondents, was the NCSCT and the second was news and media ([Table 2](#ijerph-12-15048-t002){ref-type="table"}). Over half of respondents said they would not recommend e-cigarettes to any of their clients. Contrastingly, less than 5% would recommend e-cigarettes to all their clients.

Respondents were asked whether they agreed with eight statements. Over three-quarters agreed that that e-cigarettes should not be recommended by SSS until there is good evidence on safety and effectiveness but two-thirds agreed that if they were licensed that they would recommend them and nearly 60% agreed that they should only be available as a licensed medication. Just under a fifth thought that e-cigarettes should be available anywhere as a consumer product. Only about half agreed that e-cigarettes normalize cigarette smoking although only a tenth agreed that e-cigarettes denormalise smoking. About a quarter of respondents had become less positive about e-cigarettes over the last 12 months; nevertheless about a quarter also thought that e-cigarettes were a good thing.

The variables which were significantly associated with both role in the service and opinion of e-cigarettes and were thus candidates for entry into the multivariate analyses were the following sources of information: ASH briefing and website, WHO report on electronic cigarettes and experienced e-cigarette users; the following statements: "Over the past 12 months I've become less positive about e-cigarettes", "if an e-cigarette was a licensed medication, I would definitely recommend them to clients", and "e-cigarettes denormalise cigarette smoking" and the final variable was whether respondents would recommend clients wanting to use electronic cigarettes at times when they cannot smoke (temporary abstinence).

### 3.2.2. Spread of Service Providers Stances on E-Cigarettes (Bivariate Analyses) {#sec3dot2dot2-ijerph-12-15048}

The largest regional representation was from London and the southeast and the smallest was from the northeast ([Table 3](#ijerph-12-15048-t003){ref-type="table"}). Respondents working in London made up a higher proportion of those positive about e-cigarettes compared with those in the north of England.

Nearly half of respondents were employed by GP practices or pharmacies whereas managers/commissioners were most likely to be employed by a hospital trust or directly by a local authority. Those employed by GPs and hospitals were less likely to hold a positive opinion of e-cigarettes whereas those employed by mental health trusts or local authorities were more positive. Nearly two-thirds of respondents were practitioners, 8% were managers, and 1% were commissioners. Commissioners and managers made a larger than expected proportion of those positive about e-cigarettes whereas practitioners made up a smaller than expected proportion.

ijerph-12-15048-t002_Table 2

###### 

Respondent knowledge and attitudes by role in services and opinion on e-cigarettes.

  Variable                                                                                                                     Distribution   Role in Services   Opinion on E-Cigs                                                                 
  ---------------------------------------------------------------------------------------------------------------------------- -------------- ------------------ ------------------- ------ ----- ------ -------------- ----- ------ ------ ------ --------------
  *Sources of information on e-cigs*                                                                                                                                                                                                               
  NCSCT briefing and website                                                                                                   1155           65.6               126                 78.8   821   68.2   *p* = 0.009    281   65.5   863    65.9   *p* = 0.933
  The news and media                                                                                                           797            45.3               74                  46.3   549   45.6   *p* = 0.951    203   47.3   586    44.7   *p* = 0.380
  Training courses                                                                                                             670            38.0               56                  35.0   496   41.2   *p* = 0.155    165   38.5   501    38.2   *p* = 0.982
  ASH briefing and website                                                                                                     585            33.2               109                 68.1   383   31.8   *p* \< 0.001   173   40.3   407    31.1   *p* = 0.001
  WHO report on electronic cigarettes                                                                                          517            29.4               74                  46.3   320   26.6   *p* \< 0.001   143   33.3   369    28.2   *p* = 0.048
  Experienced electronic cigarette users                                                                                       457            26.0               54                  33.8   302   25.1   *p* = 0.025    169   39.4   285    21.8   *p* \< 0.001
  The websites of electronic cigarette companies                                                                               189            10.7               20                  12.5   122   10.1   *p* = 0.436    61    14.2   127    9.7    *p* = 0.011
  The websites of vaping organisations                                                                                         114            6.5                26                  16.3   63    5.2    *p* \< 0.001   39    9.1    74     5.6    *p* = 0.017
  *Respondents agreed or strongly agreed (compared with neither agreed or disagreed, disagreed or strongly disagreed) that:*                                                                                                                       
  E-cigs are a good thing?                                                                                                     429            24.4               60                  38.0   264   22.2   *p* \< 0.001                              
  Over the past 12 months I\'ve become less positive about e-cigs                                                              495            28.1               31                  19.5   362   30.7   *p* = 0.005    34    8.0    457    35.2   *p* \< 0.001
  E-cigs should not be recommended by SSS until there is good evidence on safety & effectiveness                               1342           76.2               118                 74.7   944   79.7   *p* = 0.180    234   54.9   1101   84.9   *p* \< 0.001
  If an e-cig was a licensed medication, I would definitely recommend them to clients                                          1148           65.2               121                 76.6   790   66.5   *p* = 0.014    375   88.0   765    58.9   *p* \< 0.001
  E-cigs should only be available as a licensed medication                                                                     1036           58.8               97                  61.0   752   63.5   *p* = 0.597    164   38.7   863    66.6   *p* \< 0.001
  E-cigs should be able to be bought anywhere by smokers as a consumer product                                                 325            18.5               34                  21.7   203   17.2   *p* = 0.202    193   45.7   130    10.0   *p* \< 0.001
  E-cigs normalise cigarette smoking                                                                                           950            53.9               88                  55.7   670   57.2   *p* = 0.791    140   33.3   804    62.4   *p* \< 0.001
  E-cigs denormalise cigarette smoking                                                                                         190            10.8               29                  19.5   118   10.3   *p* = 0.001    66    15.9   124    9.9    *p* = 0.001
  *Client groups to which respondents would recommend e-cigarettes*                                                                                                                                                                                
  All my clients                                                                                                               82             4.7                10                  6.3    45    3.7    *p* = 0.193    58    13.5   23     1.8    *p* \< 0.001
  Clients who are already using e-cigs                                                                                         324            18.4               40                  25.0   219   18.2   *p* = 0.051    138   32.2   184    14.0   *p* \< 0.001
  Clients wishing to cut down but not stop                                                                                     215            12.2               24                  15.0   139   11.6   *p* = 0.258    104   24.2   111    8.5    *p* \< 0.001
  Clients wanting to use electronic cigarettes at times when they cannot smoke (temporary abstinence)                          212            12.0               31                  19.4   131   10.9   *p* = 0.003    105   24.5   107    8.2    *p* \< 0.001
  Clients who wish to cut down before they stop                                                                                204            11.6               22                  13.8   129   10.7   *p* = 0.312    101   23.5   102    7.8    *p* \< 0.001
  Clients who have tried and failed to quit many times                                                                         355            20.2               34                  21.3   236   19.6   *p* = 0.703    167   38.9   187    14.3   *p* \< 0.001
  More dependent smokers                                                                                                       199            11.3               23                  14.4   118   9.8    *p* = 0.100    98    22.8   100    7.6    *p* \< 0.001
  None of my clients                                                                                                           983            55.8               82                  51.2   693   57.6   *p* = 0.150    122   28.4   850    64.9   *p* \< 0.001
                                                                                                                                                                                                                                                   

ijerph-12-15048-t003_Table 3

###### 

Stances of service providers on e-cigarettes.

  Variable                                                  Role in Services   Opinion of E-Cigs                                             
  ------------------------------------------ ------ ------- ------------------ ------------------- ------ ------ ----- -------------- ------ ------
  *Region*                                                                     *p* = 0.026                             *p* = 0.015           
  North East                                 64     3.6     5                  10.4                43     89.6   10    15.6           54     84.4
  North West                                 230    13.1    23                 12.6                159    87.4   47    20.6           181    79.4
  Yorkshire & Humberside                     132    7.5     7                  7.0                 93     93.0   24    18.5           106    81.5
  East Midlands                              159    9.0     6                  5.1                 112    94.9   40    25.2           119    74.8
  West Midlands                              224    12.7    19                 10.8                157    89.2   50    22.9           168    77.1
  East of England                            151    8.6     14                 12.5                98     87.5   35    23.5           114    76.5
  London                                     290    16.5    32                 14.5                189    85.5   94    32.6           194    67.4
  South East                                 303    17.2    40                 16.9                196    83.1   81    27.1           218    72.9
  South West                                 208    11.8    14                 8.2                 156    91.8   48    23.5           156    76.5
  Total                                      1761   100.0   160                11.7                1203   88.3   429   24.7           1310   75.3
  *Organisation*                                                               *p* \< 0.001                            *p* \< 0.001          
  General Practice                           477    27.1    5                  1.3                 377    98.7   78    16.6           393    83.4
  Pharmacy                                   334    19.0    25                 8.9                 257    91.1   83    25.2           247    74.8
  Acute / Foundation Hospital Trust          255    14.5    29                 16.3                149    83.7   47    18.8           203    81.2
  Employed directly by the Local Authority   163    9.3     33                 24.6                101    75.4   53    32.9           108    67.1
  Mental Health Trust                        105    6.0     16                 21.3                59     78.7   45    43.7           58     56.3
  Private company                            104    5.9     15                 18.8                65     81.3   36    35.0           67     65.0
  Social enterprise                          56     3.2     8                  16.0                42     84.0   16    28.6           40     71.4
  Other                                      267    15.2    29                 15.9                153    84.1   71    26.8           194    73.2
  Total                                      1761   100.0   160                11.7                1203   88.3   429   24.7           1310   75.3
  *Role*                                                                                                               *p* \< 0.001          
  Commissioner                               23     1.3                                                          14    63.6           8      36.4
  Manager                                    137    7.8                                                          46    33.8           90     66.2
  Other                                      398    22.6                                                         105   26.9           286    73.1
  Stop Smoking Practitioner                  1203   68.3                                                         264   22.2           926    77.8
  Total                                      1761   100.0                                                        429   24.7           1310   75.3

Both region and organisation were significantly associated with the role the respondent played in the services and their opinion of e-cigarettes. Thus both these variables were put forward for the multivariate analyses.

### 3.2.3. Why might Commissioners and Managers be more Positive about E-Cigarettes than Practitioners? (Multivariate Analysis) {#sec3dot2dot3-ijerph-12-15048}

There were 1278 cases available for multivariate analysis out of the 1363 clients who indicated they were a practitioner, manager, or commissioner ([Table 4](#ijerph-12-15048-t004){ref-type="table"}). Managers/commissioners were approximately twice as likely to agree/strongly agree that e-cigarettes were a good thing as commissioners (OR 2.15 (1.50 to 3.08)) when role was alone in the model ([Table 4](#ijerph-12-15048-t004){ref-type="table"}). The variable that caused the largest decline in the odds ratio of role when it was entered individually was the employing organisation followed by agreement that the respondent had become less positive in the last year.

When the variables were added in a forward stepwise manner, role became non-significant (*p* \< 0.05) when three variables were added and non-significant (*p* \< 0.10) when four variables were added. Thus there was no generalizable difference in opinion on e-cigarettes of practitioners and managers/commissioners once these four variables had been taken into account. Removing each of the four variables individually confirmed the order of magnitude difference made to the odds ratio of role. The most important variable was employing organisation followed by agreement of becoming less positive in the last year, then recommendation for temporary abstinence, and finally agreement that they would recommend e-cigarettes if they were licenced.

In summary, managers/commissioners were more positive about e-cigarettes than practitioners; they were also more likely to work directly for local authorities rather than GP practices, they were less likely to say they had become less positive about e-cigarettes in the last year and they were more likely to say that they would recommend them for temporary abstinence and that they would recommend them to clients if they were licenced.

Items that did not appear to be mediators included information source about e-cigarettes, the region worked in, whether or not e-cigarettes denormalise smoking and client groups to which they would recommend cigarettes (other than temporary abstinence).

ijerph-12-15048-t004_Table 4

###### 

Reasons for manager/commissioners more positive view of e-cigarettes (strongly agree/agree that e-cigarettes are a good thing compared with neutral, disagree, or strongly disagree) rather than practitioners suggested from logistic regression models---final mediating variables.

  Variable                                             aOR of Manager/Practitioner When Variables Added in Forward Stepwise   Significance of Role   aOR of Manager/Practitioner When Variables Removed from Full Model Individually (Backwards Stepwise)
  ---------------------------------------------------- ---------------------------------------------------------------------- ---------------------- ------------------------------------------------------------------------------------------------------
  Role (manager/commissioner *vs* practitioner) only   2.15 (1.50 to 3.08)                                                                           
  Organisation                                         1.82 (1.24 to 2.65)                                                    *p* = 0.002            1.60 (1.07 to 2.37)
  Agree less positive in the last year                 1.59 (1.07 to 2.36)                                                    *p* = 0.022            1.57 (1.05 to 2.35)
  Recommend e-cigs for temporary abstinence            1.47 (0.98 to 2.20)                                                    *p* = 0.064            1.49 (0.99 to 2.23)
  Agree would recommend if licenced                    1.39 (0.91 to 2.10) ^1^                                                *p* = 0.124            1.47 (0.98 to 2.20)

^1^ This was the adjusted odds ratio (aOR) of role in the final model. In the final model respondents who were employed by mental health trusts and employed directly by local authorities were significantly more likely to have a good opinion of e-cigarettes than those employed by GP practices (aOR 3.41 (1.82 to 6.37) and 1.86 (1.12 to 3.12) respectively), respondents who agreed that they had become less positive in the last year were significantly less likely to have a good opinion of e-cigarettes generally (aOR 0.16 (0.11 to 0.26)), respondents who would recommend e-cigarettes for temporary abstinence or if they were licenced were significantly more likely to have a good opinion of e-cigarettes (aOR 2.78 (1.89 to 4.07 and aOR 3.93 (2.68 to 5.77) respectively).

### 3.2.4. Role of E-Cigarettes in Decline in SSS Uptake

E-cigarettes were seen as the most important reason for the decline in numbers attending the SSS followed by remaining smokers being harder to reach ([Table 5](#ijerph-12-15048-t005){ref-type="table"}). Thus the substantial changes in the structure and funding of SSS were less commonly cited as reasons for the decline.

ijerph-12-15048-t005_Table 5

###### 

Reasons for the decline in SSS client numbers.

  Reason                                                    N      \%
  --------------------------------------------------------- ------ ------
  Smokers choosing to use e-cigs                            1461   83.0
  Remaining smokers in the population are harder to reach   947    53.8
  Reduced mass media health campaigns                       527    29.9
  Reduced funding of services                               488    27.7
  SSS moved from NHS to LA                                  389    22.1
  Put out to tender                                         299    17.0
  Few specialist practitioners available                    243    13.8

4. Conclusions {#sec4-ijerph-12-15048}
==============

E-cigarettes were reported as being used by a very small proportion of SSS clients, but those clients were among the most successful. Nevertheless, most SSS personnel were waiting for licenced e-cigarettes to become available before recommending them to clients and less than a quarter viewed e-cigarettes as "a good thing". This is probably because evidence of effectiveness has only been recently acquired \[[@B4-ijerph-12-15048]\]. A vaping promotion organisation survey of 84 medical professionals \[[@B26-ijerph-12-15048]\] found generally positive opinions on e-cigarettes but also some ambivalence; these findings have not been peer reviewed.

Managers and commissioners were more positive about e-cigarettes than practitioners. Multivariate analysis in our study suggested that reasons for the association between role and positive feelings towards e-cigarettes might include that, firstly, practitioners were more likely to work for GP practices where staff were generally more negative whereas managers/commissioners were more likely to work directly for a local authority or mental health trust where staff were generally more positive. Secondly, practitioners were more likely to say they have become less positive in the last 12 months than personnel in other roles. Thirdly, managers and commissioners were more likely to recommend e-cigarettes for temporary abstinence than practitioners---this could be due to a wider role in tobacco control and links to networks disseminating evidence and guidance on e-cigarettes and more time to peruse new research whereas practitioners may be more focussed on their cessation role. Such differences perhaps reflect lack of dissemination of information which could be addressed by services. Innovation and improvement are most likely when there is greater sharing of information \[[@B27-ijerph-12-15048]\]. SSS personnel cited e-cigarettes as the most important reason for the decline in service footfall. Thus services should address their stance on e-cigarettes with some urgency.

In a study of adolescent health care professionals in Minnesota (U.S.), family medicine physicians knew more about e-cigarettes and were more comfortable about talking to patients about them than nurses \[[@B28-ijerph-12-15048]\] implying again that higher status professionals might be more positive; however paediatricians had similar ratings to nurses which might suggest varying interests and networks of different groups could play a role.

4.1. Limitations {#sec4dot1-ijerph-12-15048}
----------------

High quit rates from e-cigarettes uncovered from the monitoring data could be because e-cigarettes were more likely to be encouraged by services with higher quit rates generally or because of self-selection bias. Asking about e-cigarettes was a new question on monitoring returns so it was possible that use was under reported.

The online survey was very simple which meant some types of differentiation were not possible. For example, only cases with an IP address outside England or who commented that they were based elsewhere could be excluded. Thus some respondents who worked outside England could have been included if they picked a random English region (which would also reduce the accuracy of the region variable). Additionally we were unable to differentiate respondents who worked only for the SSS from personnel who were employed in another role (for example a health care assistant for a GP practice or pharmacy) which involved some smoking cessation behavioural support work.

A different issue is that we do not know the source of SSS personnel's opinions---we do not know the extent to which respondents' ideas were from personal experience with clients or from general media for example. Additionally, it is unclear the extent to which the gap between managers/commissioners and practitioners is the result of practitioners having less understanding of the scientific literature on e-cigarettes or practitioners having a better understanding because they see clients who vape day to day---and thus whether it is managers/commissioners or practitioners who are more "correct" or closer to "the truth" in their beliefs.

The data analysis in this article was cross-sectional rather than longitudinal. Tracking changes over time would be useful in future work.

4.2. Summary {#sec4dot2-ijerph-12-15048}
------------

Despite a positive approach being taken towards e-cigarettes by Public Health England \[[@B4-ijerph-12-15048]\] and the NCSCT \[[@B12-ijerph-12-15048]\], in 2014 their use was not being encouraged by many English SSS and use was only recorded by a small proportion of clients. SSS commissioners and managers need to consider how to disseminate messages about e-cigarettes effectively to all practitioners and to address practitioners' concerns.
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